Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Nasuh C. Buyukkaramikli*, Saskia de Groot, Rob Riemsma, Debra Fayter, Nigel Armstrong, Piet Portegijs, Steven Duffy, Jos Kleijnen, Maiwenn J. Al

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)141-153
Number of pages13
JournalPharmacoeconomics
Volume37
Issue number2
DOIs
Publication statusPublished - Feb 2019

Keywords

  • 1ST-LINE TREATMENT
  • ENDOCRINE THERAPY
  • LETROZOLE
  • BEVACIZUMAB
  • PALBOCICLIB
  • UTILITY

Cite this